ICU sedation, delirium & recovery
Factors associated with treatment resumption and long-term outcomes after intensive care unit (ICU) discharge in patients with hematological malignancies
Authors' conclusion
In patients with HMs, ICU survival was substantial and most deaths occurred during the ICU stay or within the first post-ICU year. Most survivors were able to resume anticancer therapy despite exhibiting functional decline. Long-term outcomes in survivors were primarily related to the nature of the underlying disease and to cardiovascular comorbidities.
Study context
- Population
- Consecutive adults with haematological malignancies (hematological malignancies (HMs)) admitted to ICU, 2014–2019
- Participants
- 252 adults
- Outcome
- Anticancer therapy resumption after ICU discharge and five-year survival
Methodological detailssingle-centre, multivariable analysis
- Single-centre
- Multivariable analysis
Main finding
As reported in the abstract
Anticancer therapy resumption and survival after ICU
- Discharged alive from ICU
- 171 (67.9%)
- Resumed treatment among 119 with indication
- 106 (89.1%)
- Regimen modifications required
- 20/103 (19.4%)
- Cardiovascular disease: lower likelihood of treatment resumption, HR
- 0.41 (95% CI 0.20-0.84; P = 0.014)
- HM diagnosed during ICU stay: higher likelihood of treatment resumption, HR
- 3.03 (95% CI 1.53-6.01; P = 0.002)
- Survival after ICU admission at 6 months
- 50.0%
- Survival at 1 year
- 46.0%
- Survival at 2 years
- 41.3%
- Survival at 3 years
- 38.9%
- Survival at 5 years
- 36.1%
- Infection: lower 5-year mortality, HR
- 0.54 (95% CI 0.33-0.87; P = 0.011)
- HM diagnosed during ICU stay: lower 5-year mortality, HR
- 0.31 (95% CI 0.12-0.81; P = 0.018)
- Other HMs: lower 5-year mortality, HR
- 0.40 (95% CI 0.19-0.86; P = 0.019)
Observational data: associations, not effects.
Further findings
Change in performance status during ICU stay
| Median change (95% CI) | P value | ||
|---|---|---|---|
| During ICU stayWorsened significantly | −1.0 (−1.0 to −1.0) | P < 0.001 | |
| −1.5−1−0.500.5Difference (linear scale) |
Most common malignancies
- Aggressive lymphoma
- 71 (28.2%)
- Acute leukemia
- 47 (18.7%)
- Multiple myeloma
- 42 (16.7%)
Original publication
Factors associated with treatment resumption and long-term outcomes after ICU discharge in patients with hematological malignancies. Ann Intensive Care. Published 8 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →